No curative treatment is currently available.3, 4Anaplastic lymphoma kinase (ALK)‐positive NSCLC constitutes a molecularly‐defined subgroup with an estimated prevalence of 2.7% of NSCLC.5 The gene discussed is ALK; the disease is non-small cell lung carcinoma.